Enhanced Self-Emulsifying Cannabidiol Formulations with Improved Bioavailability and Reduced Variability

This inventive concept relates to self-emulsifying cannabidiol compositions with improved bioavailability, reduced variability in absorption rates, and targeted release, thereby enhancing the treatment of various diseases and disorders.

The original patent disclosed self-emulsifying cannabidiol compositions, but these formulations had limitations in terms of bioavailability and variability in absorption rates, leading to inconsistent therapeutic effects. The present inventive concept addresses these limitations by introducing novel surfactant combinations, nanoparticle delivery systems, and solid dosage forms, resulting in improved efficacy and reduced side effects.

The enhanced self-emulsifying cannabidiol compositions comprise from about 1% to about 40% w/w cannabidiol and from about 40% to about 99% w/w of one or more surfactants selected from polyethylene glycol 40 hydrogenated castor oil, caprylocaproyl polyoxyl-8 glycerides, linoleoyl polyoxyl-6 glycerides, and polyglycerol polyricinoleate. These compositions exhibit improved bioavailability and reduced variability in absorption rates due to the optimized surfactant ratios and nanoparticle delivery systems. Additionally, the compositions can be formulated for oral administration in solid dosage forms, providing a convenient and patient-friendly treatment option.

The new claims introduce novel surfactant combinations, nanoparticle delivery systems, and solid dosage forms, which are not obvious from the original patent. The improved bioavailability and reduced variability in absorption rates are significant advancements over the prior art, providing a non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept may include using different surfactant combinations, varying the nanoparticle size and composition, or incorporating additional excipients to enhance the formulation's stability and efficacy. Variations of the solid dosage forms may include tablets, capsules, or powders, each with unique advantages and applications.

The enhanced self-emulsifying cannabidiol formulations have significant commercial potential in the treatment of anxiety disorders, pain management, and other diseases and disorders. The targeted release and improved bioavailability of these compositions make them attractive for pharmaceutical companies and healthcare providers seeking more effective and efficient treatment options.